What we do GSM Foils Limited manufactures blister foils and aluminium pharma strip foils for pharmaceutical packaging, ensuring product protection from moisture, oxygen, and contamination. |
Founded in 2,019 |
Market share Emerging player with growing presence in pharmaceutical aluminium foil packaging market post-IPO listing in 2024. |
Problem solved Protects sensitive pharmaceutical products by providing high-quality, durable packaging foil that prevents environmental damage and contamination. |
Top clients or who we serve Pharmaceutical manufacturers using aluminium blister and strip foils for packaging capsules and tablets; primarily B2B sector. |
Key management Sagar Girish Bhanushali (Chairman & Whole Time Director), Mohansingh Laxmansingh Parmar (Managing Director) |
Our journey and innovations Founded in 2019 as LLP, converted to Public Limited in 2023; IPO raised Rs 11 crore in 2024; expanded product line for pharma packaging foils. |
Where we operate Primarily domestic Indian market with plans to expand. |
Top products or what we offer Blister foil and aluminium pharmaceutical strip foils in various sizes and thicknesses serving pharma packaging needs. |
Top brands - |
Raw materials needed Aluminium and related materials for foil manufacturing. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue mostly recurring from ongoing supply contracts to pharmaceutical companies. |
Our industry position Newly listed, gaining foothold in pharmaceutical packaging segment with strong growth potential. |
Financial highlights FY 2024-25 revenue Rs 133.8 crore, net profit Rs 9.65 crore; strong growth from previous year. |
Geographical revenue split - |
Order book - |
Whats driving growth Rising pharma sector demand, innovative foil packaging solutions, recent IPO proceeds fueling expansion. |
Our future plans Raise Rs 23.1 crore through proposed rights issue to enhance production capacity and boost market share. |
Our green promise - |
Our people and values Committed to skilled workforce development with a focus on ethical corporate governance and transparent operations. |
Key challenges ahead Scaling operations, managing raw material costs, and competition in pharmaceutical packaging industry. |
Interesting facts Converted from LLP to Public Limited within 4 years; IPO and NSE Emerge listing in 2024. |
Risks and strategy Exposure to raw material price volatility mitigated by strategic sourcing and long-term client contracts. |
